This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Goldman Sachs Keeps Their Hold Rating on Wuxi Biologics (Cayman) (WXIBF)
In a report released today, Ziyi Chen from Goldman Sachs maintained a Hold rating on Wuxi Biologics (Cayman), with a price target of HK$33.50. The company’s shares closed last Wednesday at $5.30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Chen is a 3-star analyst with an average return of 3.9% and a 46.05% success rate. Chen covers the Healthcare sector, focusing on stocks such as China Medical System Holdings, InnoCare Pharma Ltd., and Asymchem Laboratories (Tianjin) Co., Ltd. Class H.
Wuxi Biologics (Cayman) has an analyst consensus of Strong Buy, with a price target consensus of $4.98.
The company has a one-year high of $5.61 and a one-year low of $1.45. Currently, Wuxi Biologics (Cayman) has an average volume of 4,313.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
